Reviewing Data on Lenvatinib plus Pembrolizumab Combination Treatment for Advanced Renal Cell Carcinoma - Episode 5

A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma

,

Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.

EP. 1: Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
EP. 2: Impressions of Data and Results from the CLEAR Trial
EP. 3: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma: Key Takeaways
EP. 4: Incorporating Data from the CLEAR Trial into Clinical Practice
Now Viewing
EP. 5: A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
EP. 6: A Physician’s Take on the CLEAR Trial Data
EP. 7: The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data
EP. 8: Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
EP. 9: Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
EP. 10: Risk Factors in the Management of Advanced Renal Cell Carcinoma
EP. 11: Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
EP. 12: Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
EP. 13: Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
EP. 14: Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
EP. 15: Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
EP. 16: Unmet Needs in Advanced Renal Cell Carcinoma Management
EP. 17: The Exciting Future of Advanced Renal Cell Carcinoma Management
EP. 18: Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
EP. 19: Advice for Community Oncologists Treating Renal Cell Carcinoma
EP. 20: Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma
EP. 21: Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens
EP. 22: Cytoreductive Nephrectomies for Renal Cell Carcinoma
EP. 23: Choosing Therapies for Patients with Advanced Renal Cell Carcinoma